HTA324 Recent Landscape of Drug Re-Assessments by G-BA – What Is the Impact of New Evidence on the Benefit Assessment Outcome? von Lach, K., Meletiche, D.

Volltext

Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US von Ivanova, J. I., Bergman, R. E., Birnbaum, H. G., Phillips, A. L., Stewart, M., Meletiche, D. M.

Volltext

Financial and Clinical Implications of Intramuscular Versus Subcutaneous Interferon Beta-1a in Portugal, Based on the Findings from the Cochrane Collaboration Review of First-Line... von Silverio, N, Sequeira, L, Meletiche, D

Volltext

Cost-Effectiveness of Subcutaneous Verse Intramuscular Interferon Beta-1A In Portugal Based on the Findings of Cochrane Collaboration Review of First-Line Treatments for Relapsing-... von Silverio, N, Sequeira, L, Meletiche, D

Volltext

The effect of age and sex on cost of inpatient facility encounters among patients with multiple sclerosis von Kozma, C. M., Meletiche, D. M., Phillips, A. L.

Volltext

Quality-of-Life Differences Between Patients With Episodic and Transformed Migraine von Meletiche, Dennis M., Lofland, Jennifer H., Young, William B.

Volltext

RO2 Analysis of Reimbursement Outcomes for Orphan Drugs with EMA Exceptional Circumstances Designation in France, Germany, and the UK von Lach, K., Pisarczyk, K., Beckerman, R., Meletiche, D.

Volltext

PCN118 DIRECT MEDICAL COSTS OF THE TREATMENT OF RECTAL CANCER: A REVIEW AND SYNTHESIS OF THE PUBLISHED EVIDENCE von Fujii, R., Duff, S., Meletiche, D., Beckerman, R., Schulten, J.

Volltext

PCN315 - Impact Of Time To Reimbursement Of Drug Treatments For Non-Small Cell Lung On Patient Outcomes In Europe And Latin America von Smith, N, Meletiche, D, Beckerman, R

Volltext

Impact Of Time To Reimbursement Of Drug Treatments For Non-Small Cell Lung On Patient Outcomes In Europe And Latin America von Smith, N, Meletiche, D, Beckerman, R

Volltext

PNS175 A DESCRIPTIVE ANALYSIS OF ICER ACCEPTANCE OF PHARMACEUTICAL MANUFACTURERS COMMENTS von Meletiche, D., Beckerman, R., Smith, N., Quach, D.

Volltext

PND43 - Cost-Effectiveness of Subcutaneous Verse Intramuscular Interferon Beta-1A In Portugal Based on the Findings of Cochrane Collaboration Review of First-Line Treatments for Re... von Silverio, N., Sequeira, L., Meletiche, D.

Volltext

PND33 - Financial and Clinical Implications of Intramuscular Versus Subcutaneous Interferon Beta-1a in Portugal, Based on the Findings from the Cochrane Collaboration Review of Fir... von Silverio, N., Sequeira, L., Meletiche, D.

Volltext

Medication possession ratio: implications of using fixed and variable observation periods in assessing adherence with disease-modifying drugs in patients with multiple sclerosis von Kozma, Chris M, Dickson, Michael, Phillips, Amy L, Meletiche, Dennis M

Volltext

Medical outcomes study short form 36: A possible source of utilities? von Meletiche, Dennis M., Doshi, Dilesh, Lofland, Jennifer H.

Volltext

Modelling the Impact of Persistence Improvements with an Electronic Injection Device on Escalation to 2nd Line Treatment in Patients with Relapsing Remitting Multiple Sclerosis (RR... von Meletiche, D.M, Rutkowski, T, Martin de Bustamante, M.A, Chowdhury, C.A, Beckerman, R

Volltext

Treatment adherence and other patient-reported outcomes as cost determinants in multiple sclerosis: a review of the literature von Lizán, Luis, Comellas, Marta, Paz, Silvia, Poveda, José Luis, Meletiche, Dennis M, Polanco, Carlos

Volltext

Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders von Gianfrancesco, Frank, Grogg, Amy, Mahmoud, Ramy, Wang, Ruey-Hua, Meletiche, Dennis

Volltext

PND27 RELATIONSHIP BETWEEN GAPS IN DRUGTREATMENT FOR MULTIPLE SCLEROSIS AND INCIDENCE OF EXACERBATIONS: FINDINGS FROM A NATIONAL MANAGED CARE DATABASE von Okuda, DT, Kozma, C, Dickson, M, Meletiche, D

Volltext

PND10 SWITCHING TO HIGH-DOSE HIGH-FREQUENCY INTERFERONS OR NATALIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS: A COST-EFFECTIVENESS ANALYSIS von Fincher, C, Meletiche, D, Goldberg, LD

Volltext